Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SatisfACtion: A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With Heavily Pre-treated PSMA Positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy

Next Previous
Trial Profile

SatisfACtion: A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With Heavily Pre-treated PSMA Positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 225Ac PSMA R2 (Primary) ; Gallium 68 PSMA R2
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms SatisfACtion
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 18 Apr 2025 Planned number of patients changed from 200 to 70.
  • 05 Mar 2025 Planned number of patients changed from 70 to 200.
  • 27 Feb 2025 Planned End Date changed from 18 Dec 2029 to 5 Nov 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top